Diagnostic accuracy of the small membrane filtration method for diagnosis of pulmonary tuberculosis in a high-HIV-prevalence setting

2016

Article référencé dans le Web of Science WOS:000376529200018

Boum Y., Kim S., Orikiriza P., Acuna-Villaorduna C., Vinhas S., Bonnet Maryline, Nyehangane D., Mwanga-Amumpaire J., Fennelly K. P., Jones-Lopez E. C.

Journal of Clinical Microbiology, 2016, 54 (6), p. 1520-1527 ISSN 0095-1137

Sputum acid-fast bacilli (AFB) smear microscopy has suboptimal sensitivity but remains the most commonly used laboratory test to diagnose pulmonary tuberculosis (TB). We prospectively evaluated the small membrane filtration (SMF) method that concentrates AFB in a smaller area to facilitate detection to improve the diagnostic performance of microscopy. We enrolled adults with suspicion of pulmonary TB from health facilities in southwestern Uganda. Clinical history, physical examination, and 3 sputum samples were obtained for direct fluorescent AFB smear, SMF, Xpert MTB/RIF, and MGIT culture media. Sensitivity and specificity were estimated for SMF, AFB smear, and Xpert MTB/RIF, using MGIT as the reference standard. The analysis was stratified according to HIV status. From September 2012 to April 2014, 737 participants were included in the HIV-infected stratum (146 [20.5%] were culture positive) and 313 were in the HIV-uninfected stratum (85 [28%] were culture positive). In HIV-infected patients, the sensitivity of a single SMF was 67.4% (95% confidence interval [CI], 59.9% to 74.1%); for AFB, 68.0% (95% CI, 60.6% to 74.6%); and for Xpert MTB/RIF, 91.0% (95% CI, 85.0% to 94.8%). In HIV-uninfected patients, the corresponding sensitivities were 72.5% (95% CI, 62.1% to 80.9%), 80.3% (95% CI, 70.8% to 87.2%), and 93.5% (95% CI, 85.7% to 97.2%). The specificity for all 3 tests in both HIV groups was >= 96%. In this setting, the SMF method did not improve the diagnostic accuracy of sputum AFB. The Xpert MTB/RIF assay performed well in both HIV-infected and -uninfected groups.

Santé : généralités [050] ; Entomologie médicale / Parasitologie / Virologie [052] ; Biotechnologies [084]

OUGANDA

Fonds IRD [F B010066932]

fdi:010066932